The therapeutic potential of toll-like receptor 7 stimulation in Asthma

Inflammation and Allergy - Drug Targets

Volumn 11, Issue 6, 2012, Pages 484-491

  Drake, Matthew G ^a   Kaufman, Elad H ^b   Fryer, Allison D ^a   Jacoby, David B ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b THERAVANCE INC   (United States)

Author keywords

Asthma; Bronchodilator; Inflammation; Toll like receptor 7

Indexed keywords

ALPHA INTERFERON; AZ 12441970; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; EOTAXIN; GAMMA INTERFERON; IMIQUIMOD; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 27; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; METHACHOLINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; PAXILLINE; PROSTAGLANDIN SYNTHASE; RESIQUIMOD; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AIRWAY REMODELING; ALLERGIC RHINITIS; ARTICLE; ASTHMA; BRONCHODILATING ACTIVITY; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; CELL HYPERPLASIA; DRUG TARGETING; FEVER; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INTRACELLULAR SIGNALING; MYALGIA; NONHUMAN; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFLAMMATION; RESPIRATORY VIRUS; SEPSIS; SMOOTH MUSCLE RELAXATION; TH1 TH2 BALANCE;

ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; DISEASE MODELS, ANIMAL; DRUG DESIGN; HUMANS; MICE; MOLECULAR TARGETED THERAPY; NITRIC OXIDE; TH2 CELLS; TOLL-LIKE RECEPTOR 7;

EID: 84870272235     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152812803589967     Document Type: Article

References (75)

1. Busse, W. W.; Lemanske, R. F. Jr. Asthma. N. Engl. J. Med., 2001, 344, 350-362.
2. Romagnani, S. The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both? Immunology, 2004, 112, 352-363.
3. Kawai, T.; Akira, S. Innate immune recognition of viral infection. Nat. Immunol., 2006, 7, 131-137.
4. Braun-Fahrlander, C.; Riedler, J.; Herz, U.; Eder, W.; Waser, M.; Grize, L.; Maisch, S.; Carr, D.; Gerlach, F.; Bufe, A.; Lauener, R. P.; Schierl, R.; Renz, H.; Nowak, D.; von Mutius, E.; Allergy and Endotoxin Study Team. Environmental exposure to endotoxin and its relation to asthma in school-age children. N. Engl. J. Med., 2002, 347, 869-877.
5. Cherfils-Vicini, J.; Platonova, S.; Gillard, M.; Laurans, L.; Validire, P.; Caliandro, R.; Magdeleinat, P.; Mami-Chouaib, F.; Dieu-Nosjean, M. C.; Fridman, W. H.; Damotte, D.; Sautes-Fridman, C.; Cremer, I. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J. Clin. Invest., 2010, 120, 1285-1297.
6. Ekman, A. K.; Adner, M.; Cardell, L. O. Toll-like receptor 7 activation reduces the contractile response of airway smooth muscle. Eur. J. Pharmacol., 2011, 652, 145-151.
7. Gorden, K. B.; Gorski, K. S.; Gibson, S. J.; Kedl, R. M.; Kieper, W. C.; Qiu, X.; Tomai, M. A.; Alkan, S. S.; Vasilakos, J. P. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol., 2005, 174, 1259-1268.
8. Hart, O. M.; Athie-Morales, V.; O'Connor, G. M.; Gardiner, C. M. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J. Immunol., 2005, 175, 1636-1642.
9. Nagase, H.; Okugawa, S.; Ota, Y.; Yamaguchi, M.; Tomizawa, H.; Matsushima, K.; Ohta, K.; Yamamoto, K.; Hirai, K. Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. J. Immunol., 2003, 171, 3977-3982.
10. Caron, G.; Duluc, D.; Fremaux, I.; Jeannin, P.; David, C.; Gascan, H.; Delneste, Y. Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFNgamma production by memory CD4+ T cells. J. Immunol., 2005, 175, 1551-1557.
11. Diebold, S. S.; Kaisho, T.; Hemmi, H.; Akira, S.; Reis e Sousa, C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science, 2004, 303, 1529-1531.
12. Lund, J. M.; Alexopoulou, L.; Sato, A.; Karow, M.; Adams, N. C.; Gale, N. W.; Iwasaki, A.; Flavell, R. A. Recognition of singlestranded RNA viruses by Toll-like receptor 7. Proc. Natl. Acad. Sci. U. S. A., 2004, 101, 5598-5603.
13. Atmar, R. L.; Guy, E.; Guntupalli, K. K.; Zimmerman, J. L.; Bandi, V. D.; Baxter, B. D.; Greenberg, S. B. Respiratory tract viral infections in inner-city asthmatic adults. Arch. Intern. Med., 1998, 158, 2453-2459.
14. Johnston, S. L.; Pattemore, P. K.; Sanderson, G.; Smith, S.; Lampe, F.; Josephs, L.; Symington, P.; O'Toole, S.; Myint, S. H.; Tyrrell, D. A. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ, 1995, 310, 1225-1229.
15. Gern, J. E.; Vrtis, R.; Grindle, K. A.; Swenson, C.; Busse, W. W. Relationship of upper and lower airway cytokines to outcome of experimental rhinovirus infection. Am. J. Respir. Crit. Care Med., 2000, 162, 2226-2231.
16. Message, S. D.; Laza-Stanca, V.; Mallia, P.; Parker, H. L.; Zhu, J.; Kebadze, T.; Contoli, M.; Sanderson, G.; Kon, O. M.; Papi, A.; Jeffery, P. K.; Stanciu, L. A.; Johnston, S. L. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 13562-13567.
17. Kitagawa, Y.; Yamaguchi, M.; Zhou, M.; Komatsu, T.; Nishio, M.; Sugiyama, T.; Takeuchi, K.; Itoh, M.; Gotoh, B. A tryptophan-rich motif in the human parainfluenza virus type 2 V protein is critical for the blockade of toll-like receptor 7 (TLR7)- and TLR9- dependent signaling. J. Virol., 2011, 85, 4606-4611.
18. Moller-Larsen, S.; Nyegaard, M.; Haagerup, A.; Vestbo, J.; Kruse, T. A.; Borglum, A. D. Association analysis identifies TLR7 and TLR8 as novel risk genes in asthma and related disorders. Thorax, 2008, 63, 1064-1069.
19. Roponen, M.; Yerkovich, S. T.; Hollams, E.; Sly, P. D.; Holt, P. G.; Upham, J. W. Toll-like receptor 7 function is reduced in adolescents with asthma. Eur. Respir. J., 2010, 35, 64-71.
20. Tse, S. M.; Tantisira, K.; Weiss, S. T. The pharmacogenetics and pharmacogenomics of asthma therapy. Pharmacogenomics J., 2011, 11, 383-392.
21. Peters, S. P.; Kunselman, S. J.; Icitovic, N.; Moore, W. C.; Pascual, R.; Ameredes, B. T.; Boushey, H. A.; Calhoun, W. J.; Castro, M.; Cherniack, R. M.; Craig, T.; Denlinger, L.; Engle, L. L.; DiMango, E. A.; Fahy, J. V.; Israel, E.; Jarjour, N.; Kazani, S. D.; Kraft, M.; Lazarus, S. C.; Lemanske, R. F., Jr; Lugogo, N.; Martin, R. J.; Meyers, D. A.; Ramsdell, J.; Sorkness, C. A.; Sutherland, E. R.; Szefler, S. J.; Wasserman, S. I.; Walter, M. J.; Wechsler, M. E.; Chinchilli, V. M.; Bleecker, E. R.; National Heart, Lung, and Blood Institute Asthma Clinical Research Network. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N. Engl. J. Med., 2010, 363, 1715-1726.
22. Kuhl, K.; Hanania, N. A. Targeting IgE in asthma. Curr. Opin. Pulm. Med., 2012, 18, 1-5.
23. Barnett, S. B.; Nurmagambetov, T. A. Costs of asthma in the United States: 2002-2007. J. Allergy Clin. Immunol., 2011, 127, 145-152.
24. American Lung Association: Asthma in Adults Fact Sheet. http://www.lung.org/lung-disease/asthma/resources/facts-andfigures/asthma-in-adults.html [Accessed March 7, 2012].
25. Pockros, P. J.; Guyader, D.; Patton, H.; Tong, M. J.; Wright, T.; McHutchison, J. G.; Meng, T. C. Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J. Hepatol., 2007, 47, 174-182.
26. Dudek, A. Z.; Yunis, C.; Harrison, L. I.; Kumar, S.; Hawkinson, R.; Cooley, S.; Vasilakos, J. P.; Gorski, K. S.; Miller, J. S. First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin. Cancer Res., 2007, 13, 7119-7125.
27. Bullens, D. M. A.; Ceuppens J. L. Influence of toll-like receptor ligands on the dendritic cell-T cell interactions: therapeutic options for allergic diseases. Inflamm. Allergy Drug Targets, 2008, 7, 211-216.
28. Karlsson, L.; Sun, S.; Rao, N. L.; Venable, J.; Thurmond, R. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm. Allergy Drug Targets, 2007, 6, 223-235.
29. Hemmi, H.; Kaisho, T.; Takeuchi, O.; Sato, S.; Sanjo, H.; Hoshino, K.; Horiuchi, T.; Tomizawa, H.; Takeda, K.; Akira, S. Small antiviral compounds activate immune cells via the TLR7 MyD88- dependent signaling pathway. Nat. Immunol., 2002, 3, 196-200.
30. Lee, J.; Chuang, T. H.; Redecke, V.; She, L.; Pitha, P. M.; Carson, D. A.; Raz, E.; Cottam, H. B. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 6646-6651.
31. Isobe, Y.; Tobe, M.; Ogita, H.; Kurimoto, A.; Ogino, T.; Kawakami, H.; Takaku, H.; Sajiki, H.; Hirota, K.; Hayashi, H. Synthesis and structure-activity relationships of 2-substituted-8- hydroxyadenine derivatives as orally available interferon inducers without emetic side effects. Bioorg. Med. Chem., 2003, 11, 3641-3647.
32. Clinical Trials Registry. An Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2245035 in Healthy Volunteers and Allergic Rhinitics. http://www.clinicaltrial.gov/ct2/results?term=NCT01480271 [Accessed: March 17, 2012].
33. Vignola, A. M.; Chanez, P.; Campbell, A. M.; Souques, F.; Lebel, B.; Enander, I.; Bousquet, J. Airway inflammation in mild intermittent and in persistent asthma. Am. J. Respir. Crit. Care Med., 1998, 157, 403-409.
34. Kaufman, E. H.; Jacoby, D. B. Upping the antedrug: is a novel anti-inflammatory Toll-like receptor 7 agonist also a bronchodilator? Br. J. Pharmacol., 2012, 166, 569-572.
35. Bian, T.; Yin, K. S.; Jin, S. X.; Zhang, X. L.; Zhou, J. Y.; Ma, X. Q.; Hu, J. J.; De, W. Treatment of allergic airway inflammation and hyperresponsiveness by imiquimod modulating transcription factors T-bet and GATA-3. Chin. Med. J. (Engl), 2006, 119, 640-648.
36. Jin, S. X.; Yin, K. S.; Bian, T.; Sun, P. L. Imiquimod attenuates airway inflammation and decreases the expression of thymus and activation regulated chemokine in allergic asthmatic mice. Chin. Med. J. (Engl), 2006, 119, 412-416.
37. Du, Q.; Zhou, L. F.; Chen, Z.; Gu, X. Y.; Huang, M.; Yin, K. S. Imiquimod, a toll-like receptor 7 ligand, inhibits airway remodelling in a murine model of chronic asthma. Clin. Exp. Pharmacol. Physiol., 2009, 36, 43-48.
38. Meng, L.; He, X.; Zhu, W.; Yang, X.; Jiang, C.; Sun, Q. M. B.; Zhang, S.; Xue, Q.; Xie, X.; Lu, S. TLR3 and TLR7 modulate IgE production in antigen induced pulmonary inflammation via influencing IL-4 expression in immune organs. PLoS One, 2011, 6, e17252.
39. Quarcoo, D.; Weixler, S.; Joachim, R. A.; Stock, P.; Kallinich, T.; Ahrens, B.; Hamelmann, E. Resiquimod, a new immune response modifier from the family of imidazoquinolinamines, inhibits allergen-induced Th2 responses, airway inflammation and airway hyper-reactivity in mice. Clin. Exp. Allergy, 2004, 34, 1314-1320.
40. Moisan, J.; Camateros, P.; Thuraisingam, T.; Marion, D.; Koohsari, H.; Martin, P.; Boghdady, M. L.; Ding, A.; Gaestel, M.; Guiot, M. C.; Martin, J. G.; Radzioch, D. TLR7 ligand prevents allergeninduced airway hyperresponsiveness and eosinophilia in allergic asthma by a MYD88-dependent and MK2-independent pathway. Am. J. Physiol. Lung Cell. Mol. Physiol., 2006, 290, L987-95.
41. Camateros, P.; Tamaoka, M.; Hassan, M.; Marino, R.; Moisan, J.; Marion, D.; Guiot, M. C.; Martin, J. G.; Radzioch, D. Chronic asthma-induced airway remodeling is prevented by toll-like receptor-7/8 ligand S28463. Am. J. Respir. Crit. Care Med., 2007, 175, 1241-1249.
42. Sel, S.; Wegmann, M.; Sel, S.; Bauer, S.; Garn, H.; Alber, G.; Renz, H. Immunomodulatory effects of viral TLR ligands on experimental asthma depend on the additive effects of IL-12 and IL-10. J. Immunol., 2007, 178, 7805-7813.
43. Camateros, P.; Kanagaratham, C.; Henri, J.; Sladek, R.; Hudson, T. J.; Radzioch, D. Modulation of the allergic asthma transcriptome following resiquimod treatment. Physiol. Genomics, 2009, 38, 303-318.
44. Aumeunier, A.; Grela, F.; Ramadan, A.; Pham Van, L.; Bardel, E.; Gomez Alcala, A.; Jeannin, P.; Akira, S.; Bach, J. F.; Thieblemont, N. Systemic Toll-like receptor stimulation suppresses experimental allergic asthma and autoimmune diabetes in NOD mice. PLoS One, 2010, 5, e11484.
45. Xirakia, C.; Koltsida, O.; Stavropoulos, A.; Thanassopoulou, A.; Aidinis, V.; Sideras, P.; Andreakos, E. Toll-like receptor 7- triggered immune response in the lung mediates acute and longlasting suppression of experimental asthma. Am. J. Respir. Crit. Care Med., 2010, 181, 1207-1216.
46. Duechs, M. J.; Hahn, C.; Benediktus, E.; Werner-Klein, M.; Braun, A.; Hoymann, H. G.; Gantner, F.; Erb, K. J. TLR agonist mediated suppression of allergic responses is associated with increased innate inflammation in the airways. Pulm. Pharmacol. Ther., 2011, 24, 203-214.
47. Grela, F.; Aumeunier, A.; Bardel, E.; Van, L. P.; Bourgeois, E.; Vanoirbeek, J.; Leite-de-Moraes, M.; Schneider, E.; Dy, M.; Herbelin, A.; Thieblemont, N. The TLR7 agonist R848 alleviates allergic inflammation by targeting invariant NKT cells to produce IFN-gamma. J. Immunol., 2011, 186, 284-290.
48. Marino, R.; Thuraisingam, T.; Camateros, P.; Kanagaratham, C.; Xu, Y. Z.; Henri, J.; Yang, J.; He, G.; Ding, A.; Radzioch, D. Secretory leukocyte protease inhibitor plays an important role in the regulation of allergic asthma in mice. J. Immunol., 2011, 186, 4433-4442.
49. Van, L. P.; Bardel, E.; Gregoire, S.; Vanoirbeek, J.; Schneider, E.; Dy, M.; Thieblemont, N. Treatment with the TLR7 agonist R848 induces regulatory T-cell-mediated suppression of established asthma symptoms. Eur. J. Immunol., 2011, 41, 1992-1999.
50. Biffen, M.; Matsui, H.; Edwards, S.; Leishman, A. J.; Eiho, K.; Holness, E.; Satterthwaite, G.; Doyle, I.; Wada, H.; Fraser, N. J.; Hawkins, S. L.; Aoki, M.; Tomizawa, H.; Benjamin, A. D.; Takaku, H.; McInally, T.; Murray, C. M. Biological characterisation of a novel class of toll-like receptor 7 (TLR7) agonists designed to have reduced systemic activity. Br. J. Pharmacol., 2012, 166, 573-586.
51. Vultaggio, A.; Nencini, F.; Fitch, P. M.; Fili, L.; Maggi, L.; Fanti, P.; deVries, A.; Beccastrini, E.; Palandri, F.; Manuelli, C.; Bani, D.; Giudizi, M. G.; Guarna, A.; Annunziato, F.; Romagnani, S.; Maggi, E.; Howie, S. E.; Parronchi, P. Modified adenine (9-benzyl- 2-butoxy-8-hydroxyadenine) redirects Th2-mediated murine lung inflammation by triggering TLR7. J. Immunol., 2009, 182, 880-889.
52. Vultaggio, A.; Nencini, F.; Pratesi, S.; Maggi, L.; Guarna, A.; Annunziato, F.; Romagnani, S.; Parronchi, P.; Maggi, E. The TLR7 ligand 9-benzyl-2-butoxy-8-hydroxy adenine inhibits IL-17 response by eliciting IL-10 and IL-10-inducing cytokines. J. Immunol., 2011, 186, 4707-4715.
53. Hammerbeck, D. M.; Burleson, G. R.; Schuller, C. J.; Vasilakos, J. P.; Tomai, M.; Egging, E.; Cochran, F. R.; Woulfe, S.; Miller, R. L. Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats. Antiviral Res., 2007, 73, 1-11.
54. Jurk, M.; Heil, F.; Vollmer, J.; Schetter, C.; Krieg, A. M.; Wagner, H.; Lipford, G.; Bauer, S. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol., 2002, 3, 499.
55. Gorden, K. K.; Qiu, X. X.; Binsfeld, C. C.; Vasilakos, J. P.; Alkan, S. S. Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides. J. Immunol., 2006, 177, 6584-6587.
56. Matsuda, H.; Suda, T.; Sato, J.; Nagata, T.; Koide, Y.; Chida, K.; Nakamura, H. Alpha-Galactosylceramide, a ligand of natural killer T cells, inhibits allergic airway inflammation. Am. J. Respir. Cell Mol. Biol., 2005, 33, 22-31.
57. Hachem, P.; Lisbonne, M.; Michel, M. L.; Diem, S.; Roongapinun, S.; Lefort, J.; Marchal, G.; Herbelin, A.; Askenase, P. W.; Dy, M.; Leite-de-Moraes, M. C. Alpha-galactosylceramide-induced iNKT cells suppress experimental allergic asthma in sensitized mice: role of IFN-gamma. Eur. J. Immunol., 2005, 35, 2793-2802.
58. Frotscher, B.; Anton, K.; Worm, M. Inhibition of IgE production by the imidazoquinoline resiquimod in nonallergic and allergic donors. J. Invest. Dermatol., 2002, 119, 1059-1064.
59. Shen, E.; Lu, L.; Wu, C. TLR7/8 ligand, R-848, inhibits IgE synthesis by acting directly on B lymphocytes. Scand. J. Immunol., 2008, 67, 560-568.
60. Fili, L.; Ferri, S.; Guarna, F.; Sampognaro, S.; Manuelli, C.; Liotta, F.; Cosmi, L.; Matucci, A.; Vultaggio, A.; Annunziato, F.; Maggi, E.; Guarna, A.; Romagnani, S.; Parronchi, P. Redirection of allergen-specific TH2 responses by a modified adenine through Toll-like receptor 7 interaction and IL-12/IFN release. J. Allergy Clin. Immunol., 2006, 118, 511-517.
61. Brugnolo, F.; Sampognaro, S.; Liotta, F.; Cosmi, L.; Annunziato, F.; Manuelli, C.; Campi, P.; Maggi, E.; Romagnani, S.; Parronchi, P. The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cells. J. Allergy Clin. Immunol., 2003, 111, 380-388.
62. Allen, J. E.; Bischof, R. J.; Sucie Chang, H. Y.; Hirota, J. A.; Hirst, S. J.; Inman, M. D.; Mitzner, W.; Sutherland, T. E. Animal models of airway inflammation and airway smooth muscle remodelling in asthma. Pulm. Pharmacol. Ther., 2009, 22, 455-465.
63. Selroos, O.; Pietinalho, A.; Lofroos, A. B.; Riska, H. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest, 1995, 108, 1228-1234.
64. Kaufman, E. H.; Fryer, A. D.; Jacoby, D. B. Toll-like receptor 7 agonists are potent and rapid bronchodilators in guinea pigs. J. Allergy Clin. Immunol., 2011, 127, 462-469.
65. Cates, C. J.; Jefferson, T. O.; Rowe, B. H. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst. Rev., 2008, 2, CD000364.
66. Plotkin, S. A. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis., 2008, 47, 401-409.
67. Kastenmuller, K.; Wille-Reece, U.; Lindsay, R. W.; Trager, L. R.; Darrah, P. A.; Flynn, B. J.; Becker, M. R.; Udey, M. C.; Clausen, B. E.; Igyarto, B. Z.; Kaplan, D. H.; Kastenmuller, W.; Germain, R. N.; Seder, R. A. Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. J. Clin. Invest., 2011, 121, 1782-1796.
68. Clinical Trials Registry: Dendritic Cell Vaccine for Patients With Brain Tumors. http://www.clinicaltrial.gov/ct2/show/NCT01204684?term=NCT01204684&rank=1 [Accessed March 17, 2012].
69. Stokes, J. R.; Sorkness, R. L.; Kaplan, M. R.; Castleman, W. L.; Tomai, M. A.; Miller, R. L.; Lemanske, R. F., Jr. Attenuation of virus-induced airway dysfunction in rats treated with imiquimod. Eur. Respir. J., 1998, 11, 324-329.
70. Harrison, C. J.; Miller, R. L.; Bernstein, D. I. Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrob. Agents Chemother., 1994, 38, 2059-2064.
71. Morrey, J. D.; Day, C. W.; Julander, J. G.; Blatt, L. M.; Smee, D. F.; Sidwell, R. W. Effect of interferon-alpha and interferoninducers on West Nile virus in mouse and hamster animal models. Antivir. Chem. Chemother., 2004, 15, 101-109.
72. Chen, M.; Griffith, B. P.; Lucia, H. L.; Hsiung, G. D. Efficacy of S26308 against guinea pig cytomegalovirus infection. Antimicrob. Agents Chemother., 1988, 32, 678-683.
73. Demaria, O.; Pagni, P. P.; Traub, S.; de Gassart, A.; Branzk, N.; Murphy, A. J.; Valenzuela, D. M.; Yancopoulos, G. D.; Flavell, R. A.; Alexopoulou, L. TLR8 deficiency leads to autoimmunity in mice. J. Clin. Invest., 2010, 120, 3651-3662.
74. Wang, J.; Shao, Y.; Bennett, T. A.; Shankar, R. A.; Wightman, P. D.; Reddy, L. G. The functional effects of physical interactions among Toll-like receptors 7, 8, and 9. J. Biol. Chem., 2006, 281, 37427-37434.
75. Fidock, M. D.; Souberbielle, B. E.; Laxton, C.; Rawal, J.; Delpuech-Adams, O.; Corey, T. P.; Colman, P.; Kumar, V.; Cheng, J. B.; Wright, K.; Srinivasan, S.; Rana, K.; Craig, C.; Horscroft, N.; Perros, M.; Westby, M.; Webster, R.; van der Ryst, E. The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691). Clin. Pharmacol. Ther., 2011, 89, 821-829.